Trastuzumab Deruxtecan
Commons · Question 1334 · Tabled 23 Jul 2024 · Department of Health and Social Care · Official record
Answered 19 Aug 2024
Question
Asked by Tonia Antoniazzi
To ask the Secretary of State for Health and Social Care, whether he has made representations to the National Institute for Health and Care Excellence on the availability of Enhertu for patients with HER2-low breast cancer.
Answer
Answered by Karin Smyth, 19 Aug 2024
The National Institute for Health and Care Excellence (NICE) makes recommendations on whether new medicines should be routinely funded by the National Health Service in England independently on the basis of the available evidence of costs and benefits and...